Compile Data Set for Download or QSAR
maximum 50k data
Found 160 Enz. Inhib. hit(s) with all data for entry = 6944
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160781(US10167313, Compound 48 | US9045524, 48)
Affinity DataIC50:  10nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160788(US10167313, Compound 55 | US9045524, 55)
Affinity DataIC50:  10nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160798(US10167313, Compound 65 | US9045524, 65)
Affinity DataIC50:  10nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160792(US10167313, Compound 59 | US9045524, 59)
Affinity DataIC50:  20nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160790(US10167313, Compound 57 | US9045524, 57)
Affinity DataIC50:  30nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160808(US10167313, Compound 76 | US9045524, 76)
Affinity DataIC50:  30nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160816(US10167313, Compound 85 | US9045524, 85)
Affinity DataIC50:  30nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160792(US10167313, Compound 59 | US9045524, 59)
Affinity DataIC50:  40nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160796(US10167313, Compound 63 | US9045524, 63)
Affinity DataIC50:  40nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160819(US10167313, Compound 88 | US9045524, 88)
Affinity DataIC50:  40nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US10167313, Compound 53 | US9045524, 53)
Affinity DataIC50:  60nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160849(US9045524, 123)
Affinity DataIC50:  60nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160841(US9045524, 111)
Affinity DataIC50:  80nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US10167313, Compound 53 | US9045524, 53)
Affinity DataIC50:  90nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160802(US10167313, Compound 69 | US9045524, 69)
Affinity DataIC50:  100nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160804(US9045524, 71)
Affinity DataIC50:  100nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160790(US10167313, Compound 57 | US9045524, 57)
Affinity DataIC50:  200nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160801(US10167313, Compound 68 | US9045524, 68)
Affinity DataIC50:  200nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160799(US10167313, Compound 66 | US9045524, 66)
Affinity DataIC50:  200nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160813(US10167313, Compound 82 | US9045524, 82)
Affinity DataIC50:  300nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-9(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160798(US10167313, Compound 65 | US9045524, 65)
Affinity DataIC50:  300nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160803(US9045524, 70)
Affinity DataIC50:  300nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160781(US10167313, Compound 48 | US9045524, 48)
Affinity DataIC50:  400nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160798(US10167313, Compound 65 | US9045524, 65)
Affinity DataIC50:  400nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-9(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160792(US10167313, Compound 59 | US9045524, 59)
Affinity DataIC50:  500nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160849(US9045524, 123)
Affinity DataIC50:  500nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-1(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160813(US10167313, Compound 82 | US9045524, 82)
Affinity DataIC50:  500nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-1(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160819(US10167313, Compound 88 | US9045524, 88)
Affinity DataIC50:  700nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160808(US10167313, Compound 76 | US9045524, 76)
Affinity DataIC50:  700nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US10167313, Compound 53 | US9045524, 53)
Affinity DataIC50:  800nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US10167313, Compound 53 | US9045524, 53)
Affinity DataIC50:  800nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-1(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160790(US10167313, Compound 57 | US9045524, 57)
Affinity DataIC50:  900nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160784(US10167313, Compound 51 | US9045524, 51)
Affinity DataIC50:  1.00E+3nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160816(US10167313, Compound 85 | US9045524, 85)
Affinity DataIC50:  1.00E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160819(US10167313, Compound 88 | US9045524, 88)
Affinity DataIC50:  1.10E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-9(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160781(US10167313, Compound 48 | US9045524, 48)
Affinity DataIC50:  1.20E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-1(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160798(US10167313, Compound 65 | US9045524, 65)
Affinity DataIC50:  1.20E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-1(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160827(US10167313, Compound 96 | US9045524, 96)
Affinity DataIC50:  1.30E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160788(US10167313, Compound 55 | US9045524, 55)
Affinity DataIC50:  1.40E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-1(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160792(US10167313, Compound 59 | US9045524, 59)
Affinity DataIC50:  1.40E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160801(US10167313, Compound 68 | US9045524, 68)
Affinity DataIC50:  1.50E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-9(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160813(US10167313, Compound 82 | US9045524, 82)
Affinity DataIC50:  1.60E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160802(US10167313, Compound 69 | US9045524, 69)
Affinity DataIC50:  1.80E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-7(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160796(US10167313, Compound 63 | US9045524, 63)
Affinity DataIC50:  1.80E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-1(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US10167313, Compound 53 | US9045524, 53)
Affinity DataIC50:  2.00E+3nMT: 2°CAssay Description:Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160750(US10167313, Compound 16 | US9045524, 16)
Affinity DataIC50: >2.00E+3nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160770(US10167313, Compound 37 | US9045524, 37)
Affinity DataIC50: >2.00E+3nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCaspase-3(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160769(US10167313, Compound 36 | US9045524, 36)
Affinity DataIC50: >2.00E+3nMAssay Description:To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCaspase-10(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160849(US9045524, 123)
Affinity DataIC50:  2.00E+3nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCaspase-1(Homo sapiens (Human))
Novagenesis Foundation

US Patent
LigandPNGBDBM160786(US10167313, Compound 53 | US9045524, 53)
Affinity DataIC50:  2.10E+3nMAssay Description:The inhibition of the activity of Caspase-1 to -10 by four different compounds (#53, #111, #123 & Z-DEVD-FMK used as a prodrug: z-D(OMe)E(OMe)VD(OMe)...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 160 total ) | Next | Last >>
Jump to: